Ignite Creation Date:
2025-12-25 @ 1:27 AM
Ignite Modification Date:
2026-02-20 @ 11:40 AM
Study NCT ID:
NCT01523093
Status:
COMPLETED
Last Update Posted:
2012-02-09
First Post:
2012-01-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions
Sponsor:
Ranbaxy Laboratories Limited
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-07
Start Date Type:
None
Primary Completion Date:
2006-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2006-10
Completion Date Type:
ACTUAL
First Submit Date:
2012-01-27
First Submit QC Date:
None
Study First Post Date:
2012-02-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-02-08
Last Update Post Date:
2012-02-09
Last Update Post Date Type:
ESTIMATED